{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-091629","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2026-08-06T11:15:15+00:00","discovered_at":"2026-08-06T11:20:00.387184+00:00","generated_at":"2026-08-06T11:20:29.059753+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Therapeutics Q2 2026 net loss $21.5M; cash $170.6M; ATI-052 data supports quarterly dosing","bullets":["Net loss $21.5M in Q2 2026 vs $15.4M in Q2 2025; revenue $1.6M vs $1.8M.","Cash, equivalents and marketable securities $170.6M at June 30, 2026; subsequent ATM raised $40.2M gross from 7.3M shares.","Phase 1a SAD/MAD data for ATI-052 (anti-TSLP/IL-4Rα bispecific) shows favorable safety and potential for quarterly dosing.","Top line results expected H2 2026 from Phase 1b POC trials of ATI-052 in asthma and atopic dermatitis, and Phase 2 trial of bosakitug in AD.","Plan to initiate Phase 2b program for ATI-052 and Phase 2b trial of modzatinib in lichen planus in Q4 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-091629","json":"https://secwatch.observer/filing/0001104659-26-091629.json","markdown":"https://secwatch.observer/filing/0001104659-26-091629.md","text":"https://secwatch.observer/filing/0001104659-26-091629.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/0001104659-26-091629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000110465926091629/acrs-20260806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T11:20:29.059753+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}